Serum vascular endothelial growth factor C level in patients with prostate cancer and benign prostatic hyperplasia.
OBJECTIVE
To compare serum vascular endothelial growth factor C (VEGF-C) levels in patients with benign prostatic hyperplasia (BPH) and prostate cancer (PCa) and analyze VEGF-C levels in relation to clinicopathologic parameters.


METHODS
Fifty-eight patients with PCa and 61 patients with BPH were included in this study. Serum VEGF-C levels were assessed by enzyme-linked immunosorbent assay.


RESULTS
The serum VEGF-C level for patients with PCa was 3,432.06 +/- 1,851.07 as opposed to 3,166.68 +/- 1,921.2 for patients with BPH. There was no statistically significant difference between the 2 groups (p = 0.4448). There was no correlation of VEGF-C to tumor stage, grading or the preoperative prostate-specific antigen values.


CONCLUSIONS
We cannot recommend VEGF-C serum level as a marker for tumor growth in PCa.
Voss
Martin
M
Department of Urology, University Hospital Mannheim, Mannheim, Germany.
Trojan
Lutz
L
Steidler
Annette
A
Weiss
Christel
C
Grobholz
Rainer
R
Alken
Peter
P
Michel
Maurice Stephan
MS
D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood*; D042582:Vascular Endothelial Growth Factor C / Q000097:blood*
D014408:Biomarkers, Tumor; D042582:Vascular Endothelial Growth Factor C